“An ideal product is a very well-differentiated product on the market or extremely close to the market in China. Not just approved in the U.S. or in Europe, but close or on the market in China and well-differentiated.”
-Dr. Blobel on the ideal product for SciClone in China, PharmAsia News, January 30, 2013.
As a US-based, China-focused specialty pharmaceutical company, our business model is to grow our revenue and profitability through partnerships, including in-licensing, promotion services agreements and other collaborations. Our business development strategies are focused on pursuing opportunities to expand our marketed product portfolio in the near term, and to drive longer-term growth through our development portfolio. Our portfolio is comprised solely of high-quality, differentiated products that address major medical needs, and that are manufactured according to the highest industry standards.
We have been successfully selling pharmaceuticals in China for nearly two decades. In particular, we have successfully marketed our lead product, ZADAXIN® (thymalfasin), in China, as well as a broad number of partnered products. Our long-term commitment to the China market has enabled our management team to leverage their extensive market experience and unique insight, as well as a highly visible market presence, well organized commercial infrastructure and strong supply chain relationships, including key distributors, to expand our business.
We have invested extensively in building an industry-leading compliance program, highlighted by our high-quality compliance program, zero tolerance for non-compliance, experienced management team and corporate commitment to constant evaluation and enhancement of compliance practices. We believe that this commitment to compliance has strengthened our reputation in the China pharmaceutical market, attracted high quality partners and differentiated our company from competitors.
We have a highly experienced management team and sales force, and a strong reputation for quality, execution and commitment to compliance. We believe that these attributes will support our continued execution of company strategy and strengthen our standing as a partner-of-choice.